Paired Ends: Andrew Senyei

Premium

Complete Genomics' stockholders voted to elect Andrew Senyei to the board of directors for a three-year term until the 2015 annual stockholder meeting. He serves as the managing director at Enterprise Partners Venture Capital. Previously, he was an adjunct associate professor of obstetrics, gynecology, and pediatrics at the University of California, Irvine. He holds an MD from Northwestern University and a BS from Occidental College.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.